Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor-Reference-Cited by-同舟云学术

Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor

Published:2021-03-24 Issue:5 Volume:112 Page:1963-1974
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Nishiya Naoyuki¹^ORCID,Oku Yusuke¹,Ishikawa Chie¹,Fukuda Tsutomu²^ORCID,Dan Shingo³^ORCID,Mashima Tetsuo⁴,Ushijima Masaru⁵,Furukawa Yoko¹,Sasaki Yuka¹,Otsu Keishi⁶,Sakyo Tomoko¹,Abe Masanori¹,Yonezawa Honami¹,Ishibashi Fumito⁷,Matsuura Masaaki⁸,Tomida Akihiro⁹,Seimiya Hiroyuki⁴^ORCID,Yamori Takao³,Iwao Masatomo²,Uehara Yoshimasa¹

Affiliation:

1. Division of Integrated Information for Pharmaceutical Sciences Department of Clinical Pharmacy Iwate Medical University School of Pharmacy Yahaba Japan

2. Division of Chemistry and Materials Science Graduate School of Engineering Nagasaki University Nagasaki Japan

3. Division of Molecular Pharmacology Cancer Chemotherapy Center Japanese Foundation for Cancer Research Tokyo Japan

4. Division of Molecular Biotherapy Cancer Chemotherapy Center Japanese Foundation for Cancer Research Tokyo Japan

5. Clinical Research and Medical Development Center Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan

6. Division of Developmental Biology and Regenerative Medicine Department of Anatomy Iwate Medical University Yahaba Japan

7. Division of Marine Life Science and Biochemistry Graduate School of Fisheries and Environmental Sciences Nagasaki University Nagasaki Japan

8. Teikyo University Graduate School of Public Health Tokyo Japan

9. Division of Genome Research Cancer Chemotherapy Center Japanese Foundation for Cancer Research Tokyo Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14839

Reference48 articles.

1. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

3. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

4. Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer

5. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies for enhancing non-small cell lung cancer treatment: Integrating Chinese herbal medicines with epidermal growth factor receptor-tyrosine kinase inhibitors therapy;European Journal of Pharmacology;2024-10

2. Progress on synthesis and structure-activity relationships of lamellarins over the past decade;European Journal of Medicinal Chemistry;2024-04

3. Smart Polymeric Nanoparticles in Cancer Immunotherapy;Pharmaceutics;2023-02-26

4. Recent advances in the synthesis of chromenone fused pyrrolo[2,1-a]isoquinoline derivatives;New Journal of Chemistry;2023

5. Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review;RSC Advances;2023